Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus acidophilus LA-5 + Bifidobacterium animalis subsp. lactis BB-12 + fluticasone propionate
- Development stage
- Unknown
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Topical
01
Overview
A combination therapy consisting of two probiotic strains (Lactobacillus acidophilus LA-5 and Bifidobacterium animalis subsp. lactis BB-12) administered orally, along with topical fluticasone propionate 0.005% ointment. This combination has been studied for the treatment of atopic dermatitis in adults, with efficacy shown to depend on the C-159T polymorphism of the CD14 receptor gene. The probiotics may modulate chronic inflammation through activation of the CD14 receptor, while fluticasone propionate provides anti-inflammatory effects as a corticosteroid.
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on Lactobacillus acidophilus LA-5 + Bifidobacterium animalis subsp. lactis BB-12 + fluticasone propionate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus acidophilus LA-5 + Bifidobacterium animalis subsp. lactis BB-12 + fluticasone propionate.